Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer

Cancer Biology and Therapy

Volumn 17, Issue 1, 2016, Pages 27-35

  Nakajima, Wataru ^a   Sharma, Kanika ^a   Hicks, Mark A ^a   Le, Ngoc ^a   Brown, Rikiara ^a   Krystal, Geoffrey W ^b   Harada, Hisashi ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABT 263; apoptosis; BCL 2 family; BCL XL; Noxa; small cell lung cancer; vorinostat

Indexed keywords

BIM PROTEIN; NAVITOCLAX; PROTEIN BAK; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; VORINOSTAT; ANILINE DERIVATIVE; BAK1 PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MCL1 PROTEIN, HUMAN; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; PROTEIN BCL X; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; IC50; LUNG CANCER CELL LINE; SMALL CELL LUNG CANCER; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ANILINE COMPOUNDS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; SMALL CELL LUNG CARCINOMA; SULFONAMIDES;

EID: 84957638491     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1108485     Document Type: Article

References (28)

1. D.M.Jackman, B.E.Johnson. Small-cell lung cancer. Lancet 2005; 366:1385-96; PMID:16226617; http://dx.doi.org/10.1016/S0140-6736(05)67569-1
2. M.Sato, D.S.Shames, A.F.Gazdar, J.D.Minna. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007; 2:327-43; PMID:17409807; http://dx.doi.org/10.1097/01.JTO.0000263718.69320.4c
3. W.N.WilliamJr, B.S.Glisson. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011; 8:611-9; PMID:21691321; http://dx.doi.org/10.1038/nrclinonc.2011.90
4. R.J.Youle, A.Strasser. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47-59; PMID:18097445; http://dx.doi.org/10.1038/nrm2308
5. J.E.Chipuk, T.Moldoveanu, F.Llambi, M.J.Parsons, D.R.Green. The BCL-2 family reunion. Mol Cell 2010; 37:299-310; PMID:20159550; http://dx.doi.org/10.1016/j.molcel.2010.01.025
6. J.M.Ben-Ezra, M.J.Kornstein, M.M.Grimes, G.Krystal. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994; 145:1036-40; PMID:7977636
7. N.Ikegaki, M.Katsumata, J.Minna, Y.Tsujimoto. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54:6-8; PMID:8261463
8. T.Oltersdorf, S.W.Elmore, A.R.Shoemaker, R.C.Armstrong, D.J.Augeri, B.A.Belli, M.Bruncko, T.L.Deckwerth, J.Dinges, P.J.Hajduk, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81; PMID:15902208; http://dx.doi.org/10.1038/nature03579
9. S.K.Tahir, X.Yang, M.G.Anderson, S.E.Morgan-Lappe, A.V.Sarthy, J.Chen, R.B.Warner, S.C.Ng, S.W.Fesik, S.W.Elmore, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67:1176-83; PMID:17283153; http://dx.doi.org/10.1158/0008-5472.CAN-06-2203
10. C.Tse, A.R.Shoemaker, J.Adickes, M.G.Anderson, J.Chen, S.Jin, E.F.Johnson, K.C.Marsh, M.J.Mitten, P.Nimmer, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68:3421-8; PMID:18451170; http://dx.doi.org/10.1158/0008-5472.CAN-07-5836
11. A.R.Shoemaker, M.J.Mitten, J.Adickes, S.Ackler, M.Refici, D.Ferguson, A.Oleksijew, J.M.O'Connor, B.Wang, D.J.Frost, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008; 14:3268-77; PMID:18519752; http://dx.doi.org/10.1158/1078-0432.CCR-07-4622
12. L.Gandhi, D.R.Camidge, M.Ribeiro de Oliveira, P.Bonomi, D.Gandara, D.Khaira, C.L.Hann, E.M.McKeegan, E.Litvinovich, P.M.Hemken, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29:909-16; PMID:21282543; http://dx.doi.org/10.1200/JCO.2010.31.6208
13. C.M.Rudin, C.L.Hann, E.B.Garon, M.Ribeiro de Oliveira, P.D.Bonomi, D.R.Camidge, Q.Chu, G.Giaccone, D.Khaira, S.S.Ramalingam, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18:3163-9; PMID:22496272; http://dx.doi.org/10.1158/1078-0432.CCR-11-3090
14. P.Hauck, B.H.Chao, J.Litz, G.W.Krystal. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 2009; 8:883-92; PMID:19372561; http://dx.doi.org/10.1158/1535-7163.MCT-08-1118
15. W.Nakajima, M.A.Hicks, N.Tanaka, G.W.Krystal, H.Harada. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis 2014; 5:e1052; PMID:24525728; http://dx.doi.org/10.1038/cddis.2014.6
16. M.Peifer, L.Fernandez-Cuesta, M.L.Sos, J.George, D.Seidel, L.H.Kasper, D.Plenker, F.Leenders, R.Sun, T.Zander, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44:1104-10; PMID:22941188; http://dx.doi.org/10.1038/ng.2396
17. S.Inoue, J.Riley, T.W.Gant, M.J.Dyer, G.M.Cohen. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007; 21:1773-82; PMID:17525724; http://dx.doi.org/10.1038/sj.leu.2404760
18. S.Xargay-Torrent, M.Lopez-Guerra, I.Saborit-Villarroya, L.Rosich, E.Campo, G.Roue, D.Colomer. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res 2011; 17:3956-68; PMID:21652541; http://dx.doi.org/10.1158/1078-0432.CCR-10-3412
19. L.He, K.Torres-Lockhart, N.Forster, S.Ramakrishnan, P.Greninger, M.J.Garnett, U.McDermott, S.M.Rothenberg, C.H.Benes, L.W.Ellisen. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov 2013; 3:324-37; PMID:23274910; http://dx.doi.org/10.1158/2159-8290.CD-12-0417
20. R.C.Thompson, I.Vardinogiannis, T.D.Gilmore. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One 2013; 8:e62822; PMID:23667527; http://dx.doi.org/10.1371/journal.pone.0062822
21. A.P.Wiegmans, A.E.Alsop, M.Bots, L.A.Cluse, S.P.Williams, K.M.Banks, R.Ralli, C.L.Scott, A.Frenzel, A.Villunger, et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 2011; 71:3603-15; PMID:21398407; http://dx.doi.org/10.1158/0008-5472.CAN-10-3289
22. D.Merino, S.L.Khaw, S.P.Glaser, D.J.Anderson, L.D.Belmont, C.Wong, P.Yue, M.Robati, B.Phipson, W.D.Fairlie, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119:5807-16; PMID:22538851; http://dx.doi.org/10.1182/blood-2011-12-400929
23. R.W.Rooswinkel, B.van de Kooij, M.Verheij, J.Borst. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis 2012; 3:e366; PMID:22875003; http://dx.doi.org/10.1038/cddis.2012.109
24. Z.F.Tao, L.Hasvold, L.Wang, X.Wang, A.M.Petros, C.H.Park, E.R.Boghaert, N.D.Catron, J.Chen, P.M.Colman, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett 2014; 5:1088-93; PMID:25313317; http://dx.doi.org/10.1021/ml5001867
25. A.J.`Souers, J.D.Leverson, E.R.Boghaert, S.L.Ackler, N.D.Catron, J.Chen, B.D.Dayton, H.Ding, S.H.Enschede, W.J.Fairbrother, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19:202-8; PMID:23291630; http://dx.doi.org/10.1038/nm.3048
26. F.T.Awan, J.C.Byrd. New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res 2014; 20:5869-74; PMID:25294898; http://dx.doi.org/10.1158/1078-0432.CCR-14-1889
27. H.Zhang, P.M.Nimmer, S.K.Tahir, J.Chen, R.M.Fryer, K.R.Hahn, L.A.Iciek, S.J.Morgan, M.C.Nasarre, R.Nelson, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14:943-51; PMID:17205078; http://dx.doi.org/10.1038/sj.cdd.4402072
28. W.H.Wilson, O.A.O'Connor, M.S.Czuczman, A.S.LaCasce, J.F.Gerecitano, J.P.Leonard, A.Tulpule, K.Dunleavy, H.Xiong, Y.L.Chiu, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11:1149-59; PMID:21094089; http://dx.doi.org/10.1016/S1470-2045(10)70261-8